Bacteria on tumors influences immune response and survival of patients with pancreatic cancer
Study finds specific microbiome tied to long-term survival; points to fecal transplant treatment
MD Anderson News Release August 08, 2019
A key difference between the few pancreatic cancer patients who survive long-term and the many whose disease overcomes all treatments is the bacterial signatures on their tumors that either stimulate or suppress immune response, a team led by researchers from The University of Texas MD Anderson Cancer Center reports in the journal Cell.
The researchers also showed that fecal microbiota transplants (FMT) from long-term survivors prompted immune response and stifled tumors in a mouse model of the disease by altering the bacteria on the tumor – its microbiome.
“Results of the FMT experiments represent a significant therapeutic opportunity to improve pancreatic cancer treatment by altering the tumor immune microenvironment,” said senior author Florencia McAllister, M.D., assistant professor of Clinical Cancer Prevention at MD Anderson. “There is promise here but we have a lot of work ahead.”
MD Anderson’s Pancreatic Cancer Moon Shot® has provided McAllister with funding to develop a clinical trial of fecal transplants for pancreatic cancer. The Moon Shots Program® is a collaborative effort to accelerate the development of scientific discoveries into clinical advances that save patients’ lives.
Most patients with pancreatic ductal adenocarcinoma – the most common form of pancreatic cancer – have late-stage disease when diagnosed. Just 9% survive to five years. Those with earlier stage cancer that can be surgically removed have a high recurrence rate and median survival of 24-30 months.
No genomic biomarkers have been identified that shed light on the reasons for long-term survival in that fraction of patients, McAllister said.
Long-term survivors have diverse tumor microbiome
While recent research has shown that the composition and diversity of microbes living in the digestive tract – the gut microbiome – can affect how cancer immunotherapy works, little research has focused on the bacteria in the tumor and how it might affect prognosis and survival, McAllister said. “We’ve known there are bacteria on pancreatic tumors, so we asked ‘do these bacteria have a role in cancer?’”
To launch the first such study in pancreatic cancer, McAllister and colleagues analyzed the bacterial DNA in tumors of long-term survivors matched to short-term survivors from two independent cohorts at MD Anderson and Johns Hopkins Hospital. In the MD Anderson cohort, median survival was 10 years for the long-term survivors (22 patients) and 1.6 years for the short-term survivors (21 patients). In the validation cohort from Johns Hopkins, 15 patients had overall survival greater than 10 years, and 10 survived fewer than five years.
Using 16S rRNA gene sequencing, the team found the long-term survivors had much greater diversity of bacterial species than the short-term survivors. Stratifying the MD Anderson patients only by this diversity measure showed those with high diversity had median survival of 9.66 years and those with low diversity had median survival of 1.66 years.
The diversity results were independent of other factors, such as previous therapies, body mass index, and antibiotics use, making it a predictor of survival for surgical patients and indicating the potential importance of the tumor microbiome in cancer progression.
Researchers also found marked differences in the bacterial communities found in each survivor group. The long-term survivors showed a relative abundance of Pseudoxanthomonas, Saccharropolyspora and Streptomyces. The presence of all three taxa, as well as the species Bacillus Clausii, predicted better outcomes for patients in both MD Anderson and Johns Hopkins cohorts.
Specific microbiome boosts immune attack on tumors
Immunohistochemistry showed a greater density of T cells, including the CD8-positive cell-killing variety, in the tumors of long-term survivors in both the MD Anderson and Johns Hopkins cohorts, consistent with previous research that showed more active immune response in long-term survivors.
McAllister and colleagues found a strong correlation between immune cell infiltration and the microbiome diversity of the tumors. Additional analysis showed immune infiltration and activation of T cells was associated with the three enriched bacterial types discovered on long-term survivors’ tumors.
With an apparent connection between the tumor microbiome and immune response, the team set out to find a way to change the tumor microbiome.
Using the gut microbiome to alter tumor microbiome
“You cannot modulate the tumor microbiome directly, but you can modulate the gut microbiome, and if there’s cross-talk between the gut and the tumor microbiomes, you could change the tumor microbiome indirectly,” McAllister said.
The team compared the bacteria in the gut, in the tumor and in adjacent tissue in three surgery patients. They found the gut microbiome represents about 25% of the tumor microbiome, but is absent from the normal, adjacent tissue, suggesting bacteria in the gut can colonize pancreatic tumors.
The researchers transplanted fecal microbiota from patients with advanced cancer into mice and found that the donor microbiome represented about 5% of the resultant tumor microbiome but that 70% of the overall tumor microbiome had been otherwise altered by the transplant.
“Now we know you can completely change the bacterial composition of the tumor microbiome by doing FMT,” McAllister said.
Reversing immune suppression with fecal transplants
Next, they performed stool transplants into mice from patients who had advanced pancreatic cancer, patients who had survived more than five years and had no evidence of disease, and healthy controls.
Five weeks after tumor implementation, mice that had received FMT from patients with advanced disease had much larger tumors than those that received FMT from long-term survivors (70% smaller average size) or healthy controls (50% smaller average size).
Immune profiling showed the mice that received the FMT from long-term survivors had significantly higher numbers and greater activation of CD8-positive T cells compared to the other two groups. Those who received FMT from advanced-stage patients had increased regulatory T cells and myeloid-derived suppressor cells, both of which suppress immune response.
To evaluate whether the effect of FMT relies on the immune system, the team depleted T cells in a group of mice treated with the long-term survivor FMT, which completely blocked the anti-tumor effect of the transplant.
Co-authors with McAllister are first authors Erick Riquelme, Ph.D., and Yu Zhang, Ph.D., both of Clinical Cancer Prevention. Other co-authors from that department are Maria Montiel, M.D., Michelle Zoltan, Pompeyo Quesada, Vidhi Chandra, Hanwen Xu, Ph.D., and Samir Hanash, M.D., Ph.D.; Liangliang Zhang, Ph.D., Wenli Dong, Lei Feng, Kim-Anh Do, Ph.D., and Christine Peterson, Ph.D., of Biostatistics; Robert Jenq, M.D., and Jennifer Wargo, M.D., of Genomic Medicine; Anthony San Lucas, Ph.D., and Paul Scheet, Ph.D., of Epidemiology; Jared Burks, Ph.D., of Leukemia; Ching-Wei D. Tzeng, M.D., Michael Kim, M.D., Matthew Katz, M.D., of Surgical Oncology; Anirban Maitra, M.B.B.S., of Sheikh Ahmed Pancreatic Cancer Research Center at MD Anderson; Ismet Sahin, Ph.D., of Texas Southern University; Deborah Nejman, Ph.D., and Ravid Straussman, M.D., Ph.D., of Weizmann Institute of Science, Rehovot, Israel; Cynthia Sears, M.D., and Laura Wood, M.D., of Johns Hopkins University School of Medicine; James Robert White, Ph.D., of Resphera Biosciences, Baltimore, MD, and Nadim Ajami, Ph.D., and Joseph Petrosino, Ph.D., of Baylor College of Medicine.
This research was funded by the American Gastroenterological Association Research Foundation, PanCAN/AACR Career Development Award, MD Anderson Philanthropic Funds, MD Anderson’s Moon Shots Program, Emerson Collective Award, NCI K12 Paul Calabresi Clinical Scholarship Award, Stand Up To Cancer-Lustgarten Foundation grant, a grant from the National Cancer Institute of the National Institutes of Health R25E (CA056452) and MD Anderson's Cancer Center Support Grant from the NCI (CA016672).
McAllister, Riquelme and Zhang are filing a patent based on findings presented in this paper. Other declarations of interests are available in the paper.
Watch Dr. Florencia McAllister discuss the study's findings.